Cambridge, United States
Anchiano Therapeutics, established in 2004, is a biopharmaceutical company based in the United States. The company operates at the intersection of Biotechnology, Health Care, and Medical Devices, focusing on the discovery, development, and commercialization of novel targeted cancer therapies. Their commitment is encapsulated by their slogan: "Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer".
The firm's most recent fundraising activity was a $23.00M Post-IPO Equity investment on April 13, 2018. Notable investors included Shavit Capital and Clal Biotechnology Industries, underscoring investor confidence in Anchiano's potential to innovate within oncology therapeutics. Such financial backing reveals a strategic interest in Anchiano's capabilities to advance medical treatments in a high-demand sector.
